Affluent Medical announces several key appointments for Medical and Clinical affairs.
|
EQS-News: Affluent Medical SA
/ Key word(s): Miscellaneous
Affluent Medical announces several key appointments for Medical and Clinical affairs.
Aix-en-Provence, March 11, 2025 – 5:45 p.m. CET – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME – "Affluent"), a French clinical-stage medical technology company specializing in the development and industrialization of implantable innovative medical devices, today announced three key leadership appointments. These strategic additions aim to accelerate the company’s progress towards market access for its advanced product pipeline. New Chief Medical Officers to Drive Specialized Platforms Affluent Medical has appointed Dr. Howard C. Herrmann as strategic Chief Medical Officer (CMO) for its Structural Heart Platform and Pr. Nicolas Barry Delongchamps as strategic CMO for its Urology Platform. These key appointments underscore Affluent Medical commitment to enhancing its clinical expertise and driving innovation as it advances its groundbreaking devices, including mitral ring KALIOSTM, mitral valve EPYGON and artificial urinary sphincter ARTUS. Dr. Howard C. Herrmann, a renowned interventional cardiologist, is Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania and Director of Interventional Cardiology at the Hospital of the University of Pennsylvania, Philadelphia. With over three decades of experience in transcatheter device therapies for valvular and structural heart diseases, he has authored over 500 publications and served as President of the Pennsylvania Chapter of the American College of Cardiology. His profound expertise in structural heart care will guide the development of Affluent’s next-generation structural heart devices. Pr. Nicolas Barry Delongchamps, a distinguished urologist and professor at Paris-Cité University, brings extensive expertise in minimally invasive surgery for benign prostatic hyperplasia and urinary incontinence. His knowledge and experience with urinary incontinence will support Affluent Medical's strategy in urology, driving innovation in this critical area. Expanding Operational Expertise with New Director of Clinical Operations Further bolstering its operational capabilities, Affluent Medical has named Federica Azzimonti as Director of Clinical Operations. With close to 25 years of experience in managing international clinical studies across cardiovascular and other medical specialties, Federica brings a wealth of expertise in trial optimization and execution. In collaboration with both strategic CMOs, she will lead the operational aspects of Affluent Medical clinical trials, ensuring streamlined execution as the company prepares for pivotal stages. “These appointments come at a crucial time as we enter our next phase of growth, transitioning into pivotal phases and continuing to progress towards commercialization of our devices.” said Sébastien Ladet, CEO of Affluent Medical. “The addition of strong medical experts has been a deliberate move that demonstrates Affluent Medical commitment to execute and to offer the best available therapies worldwide.”
About Affluent Medical’s Specialized Platforms MITRAL RING KALIOSTM: KaliosTM is the only mitral annuloplasty device that can be simply adjusted percutaneously by a cardiologist to treat both residual or recurrent mitral valve insufficiency, at any time after implantation, repeatedly and with a beating heart, thereby avoiding repeat open-heart surgery. Affluent Medical believes that KaliosTM would avoid further intervention for potentially 30% to 40% of patients over a five-year horizon. Following positive feedback from the FDA in September 2024, Affluent Medical’s objective is to submit a De Novo application with current clinical data at the end of 2025/early 2026 to be followed by commercial launch, subject to Edwards’ decisions, with whom Affluent Medical has signed several agreements related to its structural heart products (adjustable mitral annulus Kalios™) and technologies (mitral valve technology). MITRAL VALVE EPYGON: Epygon is the only biomimetic mitral heart valve that mimics the anatomy of the native mitral valve and physiological blood flow, able to be implanted via a transcatheter route. This transcatheter approach avoids an invasive open-heart procedure and associated complications to treat mitral valve insufficiency. In 2024, the company began a collaboration with Prof. Mohammad Sarraf, MD, interventional cardiologist at the Mayo Clinic in the US, to evaluate the benefits of the biomimetic design of the Epygon valve. This innovative design aims to replicate the anatomy and natural physiology of the native mitral valve to enable patients to recover good cardiac function more quickly. During the first half of 2024, Affluent Medical accelerated patient screening, achieving a fourfold increase in the number of patients screened by the end of June 2024 with the goal to implant up to ten patients to complete the pilot phase. URINARY SPHINCTER ARTUS: Artus is the first artificial urinary sphincter that can be activated by the patient with a simple remote control for the treatment of moderate to severe urinary incontinence. Urinary incontinence is a major public health problem for over 400 million people worldwide without any innovation in the last 40 years, causing patients to suffer a reduced quality of life associated with the psychological disorders related to the disease. In January 2025, the Company announced the completion of the enrollment for the pilot phase of the European multicenter clinical study in humans with the successful 10th minimally invasive implantation of the Artus urinary sphincter with, to date, 100% of devices having been successfully activated and the safety profile remains positive. The pivotal phase, aiming to validate the device’s performance in reducing incontinence in several dozen patients, is scheduled to begin in Q2 2025. With women representing about 80% of patients suffering from urinary incontinence, the Company will submit the dossier in order to begin a pilot study in women in the first half of 2025, aiming to extend indications for its Artus urinary sphincter.
About Affluent Medical Affluent Medical is a French medical technologies company, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases, one of the world's leading causes of mortality, and urinary incontinence, which currently affects one in four adults. Affluent Medical develops next-generation implants that are minimally invasive, innovative, adjustable and biomimetic, designed to restore essential physiological functions. The candidate products developed by the Company are all undergoing clinical studies in humans. Subject to raising the funds necessary to finance its strategy and the positive results of ongoing clinical studies, the Company aims to gradually market its products from 2026, directly or indirectly. For more information, please visit www.affluentmedical.com
Contacts:
11.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Affluent Medical SA |
| 320 avenue Archimède - Les pléiades III Batiment B | |
| 13100 Aix-en-Provence | |
| France | |
| E-mail: | affluent@mc-services.eu |
| Internet: | www.affluentmedical.com |
| ISIN: | FR0013333077 |
| EQS News ID: | 2098768 |
| End of News | EQS News Service |
|
|
2098768 11.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.